Anavex Life Sciences financials
$2.02−14.41%
Close Sep 30, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Sep 30 | FY24 Sep 30 | FY23 Sep 30 | FY22 Sep 30 | FY21 Sep 30 | FY20 Sep 30 | FY19 Sep 30 | FY18 Sep 30 | FY17 Sep 30 | FY16 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$51.4M | -$52.9M | -$55.8M | -$51.0M | -$42.0M | -$31.1M | -$29.1M | -$19.3M | -$15.7M | -$15.6M |
| Net income | -$46.4M | -$43.0M | -$47.5M | -$48.0M | -$37.9M | -$26.3M | -$26.3M | -$17.3M | -$13.5M | -$14.7M |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.54 | $-0.52 | $-0.60 | $-0.62 | $-0.54 | $-0.45 | $-0.54 | $-0.39 | $-0.33 | $-0.42 |
| EBITDA | -$51.4M | -$52.9M | -$55.8M | -$51.0M | -$42.0M | -$31.1M | -$29.1M | -$19.3M | -$15.7M | -$15.6M |
| Operating cash flow | -$39.0M | -$30.8M | -$27.8M | -$24.2M | -$30.4M | -$21.3M | -$18.5M | -$12.6M | -$9.0M | -$9.2M |
| Free cash flow | -$39.0M | -$30.8M | -$27.8M | -$24.2M | -$30.4M | — | — | — | — | — |
| Diluted shares | 85.3M | 83.5M | 79.8M | 76.9M | 69.8M | 58.2M | 48.9M | 44.7M | 40.8M | 35.2M |
Balance sheet
| Period end | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $102.6M | $132.2M | $151.0M | $149.2M | $152.1M | $29.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $103.8M | $135.6M | $154.4M | $152.7M | $161.6M | $34.5M |
| Total liabilities | $8.9M | $15.3M | $12.5M | $10.2M | $10.8M | $7.3M |
| Shareholders' equity | $94.9M | $120.3M | $141.9M | $142.5M | $150.8M | $27.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology